# AudioCure Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/audiocure-pharma

- Industry: Pharmaceuticals
- Headquarters: Berlin, Germany
- Website: www.audiocure.com/
- Total disclosed funding: $10M
- Latest round: Series A (Jul 27, 2016)
- Investors on record: 2

## About

AudioCure Pharma GmbH, based in Berlin, Germany, focuses on developing innovative pharmacological treatments for hearing disorders, particularly targeting conditions such as tinnitus and sensorineural hearing loss.Founded in 2012 in Berlin, Germany, AudioCure Pharma GmbH is engaged in the research and development of drug therapies aimed at repairing hearing impairments. The company has completed a total of 3 deals, with its most recent funding round being a Series A raising EUR 9.00 mn from lead investor MED-EL and others. The company's current valuation is EUR 36.265 mn. CEO Reimar Schlingensiepen oversees operations alongside founders Raik Madla and Ulrich Traugott.AudioCure Pharma GmbH specializes in the development of innovative drug treatments for hearing disorders, focusing on conditions such as sensorineural hearing loss and tinnitus, which currently lack approved pharmacological therapies. The company's lead product candidate, AC102, is a novel molecule designed to protect and restore the cellular components essential for hearing within the inner ear. This therapeutic approach addresses the root causes of these disorders rather than merely alleviating symptoms, potentially marking a significant advancement in the treatment of acute hearing loss and acute tinnitus. AudioCure targets a broad client base, including healthcare providers, hospitals, and research institutions, primarily within Europe and North America, where there is a high prevalence of hearing disorders among the population. Their mission is to turn what has historically been considered incurable into manageable medical conditions, transforming the treatment landscape for millions suffering from hearing impairments.In 2022, AudioCure Pharma GmbH reported a revenue of EUR 632,279.3. The company operates within a pharmaceutical framework that involves B2B transactions, generating revenue primarily from partnerships with pharmaceutical distributors and healthcare providers, as well as direct sales of their flagship product AC102 to hospitals and clinics. Collaborative agreements with research institutions may also contribute to revenue through grant funding or milestone payments.In February 2025, AudioCure Pharma GmbH raised funding led by new investor InfectoPharm, with participation from returning investors MED-EL and High-Tech Gruenderfonds, to accelerate the development of its drug candidate AC102. The company aims to expand its reach into new markets within Europe and North America by enhancing its product offerings and increasing engagement with healthcare providers. Recent funding will support initiatives designed to promote AC102's clinical studies and regulatory approvals, paving the way for more comprehensive market penetration.

## Funding rounds

- Series A, Jul 27, 2016, $10M — High-Tech Gruenderfonds, MED-EL
- Seed, May 29, 2012 — High-Tech Gruenderfonds

## Investors

- High-Tech Gruenderfonds (https://capitalatlas.ai/funds/high-tech-gruenderfonds) — Seed, Series A
- MED-EL — Series A